{"id":97943,"date":"2026-07-06T06:23:15","date_gmt":"2026-07-06T06:23:15","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/97943\/"},"modified":"2026-07-06T06:23:15","modified_gmt":"2026-07-06T06:23:15","slug":"brandon-capital-announces-agreement-for-novartis-to-acquire-portfolio-company-myricx-bio-to-advance-new-class-of-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/97943\/","title":{"rendered":"Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics"},"content":{"rendered":"<p>MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) &#8212; Brandon Capital, Australasia\u2019s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis. The transaction is valued at up to US$1.5 billion (~A$2.16bn) including an upfront cash payment of US$1.1 billion (~A$1.58bn) plus potential milestone payments.<\/p>\n<p>Myricx Bio\u00a0is a UK-based pre-clinical oncology company developing a novel class of payloads for antibody-drug conjugates (ADCs). One of the most important emerging modalities in cancer therapy, ADCs combine the targeting precision of antibodies with the tumour-killing activity of potent small-molecule payloads. The acquisition advances ADC innovation by bringing together the strengths of Novartis in oncology with Myricx\u2019s two lead ADC assets and its next-generation N-myristoyltransferase inhibitor (NMTi) payload platform with potential impact across multiple solid tumour settings.<\/p>\n<p>Brandon Capital played an instrumental role in the\u00a0formation of Myricx Bio, a spin out from Imperial College London and the Francis Crick Institute. It was co-founded by Brandon Capital\u00a0Venture Partner Dr.\u00a0Roberto Solari who served as Myricx Bio\u2019s founding CEO. Brandon Capital was joint founding seed investor in 2019. Managing Partner Dr. Stephen Thompson led the investment, providing strategic and operational support through its capital-efficient early development and subsequent financings, maintaining a substantial shareholding through to acquisition, led by Myricx Bio CEO Mohit Rawat.<\/p>\n<p>The exit\u00a0will generate a\u00a0significant return for Brandon Capital\u2019s investors, Australian superannuation (pension) funds Hostplus, HESTA and Aware Super as well as CSL and QIC. It further strengthens the firm\u2019s\u00a0track record\u00a0of building globally competitive life sciences companies from breakthrough academic science.\u00a0<\/p>\n<p>Brandon Capital UK-based Partner Dr. Jonathan Tobin joined Myricx Bio as Executive Director in 2023 to help build the company\u2019s ADC capability and raise the Series A. He is a co-inventor on one of Myricx Bio\u2019s\u00a0ADC patents alongside Dr. Solari and\u00a0Myricx Bio\u00a0CSO Dr. Francesca Zammarchi.\u00a0<\/p>\n<p>Get the latest news<br \/>\n                <br class=\"br-line\"\/><br \/>\n                delivered to your inbox<\/p>\n<p>Sign up for The Manila Times newsletters<\/p>\n<p>            By signing up with an email address, I acknowledge that I have read and agree to the <a href=\"https:\/\/www.manilatimes.net\/terms-of-service\" title=\"Terms of Service\" rel=\"nofollow noopener\" target=\"_blank\">Terms of Service<\/a> and <a href=\"https:\/\/www.manilatimes.net\/privacy-policy\" title=\"Privacy Policy\" rel=\"nofollow noopener\" target=\"_blank\">Privacy Policy<\/a>.<\/p>\n<p>Dr.\u00a0Jonathan\u00a0Tobin,\u00a0Myricx Bio Director\u00a0and\u00a0Partner at Brandon Capital said, &#8220;Congratulations to Mohit Rawat, Robin Carr and the Myricx Bio team. This acquisition by Novartis is a testament to the phenomenal work of Myricx Bio\u2019s founders and management, and a powerful validation of Brandon Capital\u2019s approach of backing world-class science before it is obvious to others.\u201d\u00a0<\/p>\n<p>Mohit Rawat, Myricx Bio CEO said, &#8220;Building biotech companies from early-stage concepts into medicines that improve patients\u2019 lives takes time, conviction and, of course capital. Brandon Capital recognised the potential of NMT inhibition early, and has been a highly supportive investor, enabling us to have advanced NMTi-ADCs with the promise as an entirely new class of cancer therapeutics.\u201d<\/p>\n<p>Brandon Capital is building\u00a0a track record\u00a0of strong returns through both early- and mid-stage exits, while also supporting companies through to commercialisation.<\/p>\n<p>Dr.\u00a0Stephen\u00a0Thompson, former Myricx\u00a0Bio Director and Managing Partner at\u00a0Brandon Capitalsaid, &#8220;Myricx Bio encapsulates\u00a0the kind of company we exist to build: a bold, potentially first-in-class therapeutic platform with the promise to deliver both exceptional investor returns and meaningful benefit for patients. This exit positions the firm well to continue attracting capital to support our existing portfolio and to back the next generation of breakthrough biomedical companies.\u201d\u00a0<\/p>\n<p>            <a data-fancybox=\"gallery\" href=\"https:\/\/manilatimes.net\/manilatimes\/uploads\/images\/2026\/07\/06\/1125420.jpg\" data-caption=\"\" rel=\"nofollow noopener\" target=\"_blank\"><\/p>\n<p>                        <img decoding=\"async\" class=\"lazy\" src=\"https:\/\/manilatimes.net\/manilatimes\/uploads\/images\/2026\/07\/06\/1125420.jpg\" alt=\"No Image\" data-alt- data-default- width=\"100%\" height=\"100%\" onerror=\"this.src=\" https:=\"\"\/><\/p>\n<p>            <\/a><\/p>\n<p>Caption: Brandon Capital Partner Dr. Jonathan Tobin (left) and Managing Partner Dr. Stephen Thompson (right).<\/p>\n<p>Note &#8211; The transaction is expected to close in H2 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals.<\/p>\n<p>Myricx Bio announcement <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6GSiL4Cl89f-dlmofr9kEarvX0_rxgAnAe6qmpNz6bHaWCY3949mce4FktwMWR1kOrgDaxdjF2AmPdwA-dhRloS3o9DqbhjfKaF0cT2K30PyuJyf2h_EFwl5L00RhfirmZdI-wsw59nlXeyHup_qwnrc4coeF2XeuxVMXzGowIiIuC9LZYsEsB7fXdtAGTObsZAShkjP-qlwtxizxu7Bk6bLF6a3EPtzR3qv7BuTUnk=\" rel=\"nofollow noopener\" target=\"_blank\">HERE<\/a><\/p>\n<p>Novartis news room <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6GSiL4Cl89f-dlmofr9kEcVXmonso2wRkEbn_-4RvvQV6e5QqwlAj9TfeT9DFBqC1oHRR_yRiS-jJKW-DGHYXw==\" rel=\"nofollow noopener\" target=\"_blank\">HERE<\/a><\/p>\n<p>About Brandon Capital\u2019s history in Myricx Bio<\/p>\n<p> Myricx Bio platform and pipeline Myricx\u00a0Bio is a UK-headquartered oncology company. It has developed N-myristoyltransferase inhibitors (NMTi), as a payload platform that has the potential to overcome\u00a0limitations of current ADCs, including resistance and toxicity.\u00a0 Its pipeline of proprietary of NMTi-ADCs are directed against established cancer targets, B7-H3 and HER2.Myricx Bio early history, 2019 &#8211; 2023<\/p>\n<p> Brandon Capital played an instrumental role in the\u00a0formation and development of Myricx Bio, identifying\u00a0the opportunity to exploit the novel biology of NMT for the development of first-in-class cancer medicines.<\/p>\n<p>Dr\u00a0Roberto Solari, Venture Partner at Brandon Capital and\u00a0former\u00a0Visting\u00a0Professor at Imperial College London,\u00a0co-founded Myricx Bio with Professor Ed Tate and Dr Andy Bell with support from Cancer Research UK. Dr Solari served as its founding\u00a0CEO, recruiting industry veteran\u00a0and former colleague and Brandon Capital Advisor Dr\u00a0Robin\u00a0Carr to lead drug development and subsequently become CEO.\u00a0<\/p>\n<p>Brandon Capital worked alongside co-founding seed investor Sofinnova Partners, helping to recruit senior leadership and shaping the company\u2019s strategy. It supported Myricx Bio\u00a0in a capital-efficient programme of early-stage experiments that\u00a0ultimately led\u00a0to the company\u2019s successful pivot into ADCs.\u00a0<\/p>\n<p>Myricx Bio focus on ADCs, 2023 &#8211; 2026<\/p>\n<p> Realising the potential of NMTis as ADC payloads,\u00a0Brandon Capital supported\u00a0a\u00a0strategic pivot, with Partner Dr Jonathan Tobin joining\u00a0Myricx Bio as Executive Director in 2023. There was no ADC expertise inside Myricx\u00a0Bio at the time, so Brandon Capital got directly involved, helped rebuild the team, and supported the company through a rapid and highly effective transformation.\u00a0<\/p>\n<p>In 2024,\u00a0Myricx Bio\u00a0raised a \u00a390m\u00a0(A$172m) Series A round co-led by Novo Holdings and Abingworth, with new investors British Business Bank and Eli Lilly joining the round alongside Cancer Research Horizons, Sofinnova Partners and Brandon Capital. At the time this was the largest Series A of a UK academic start-up company. Myricx Bio recruited Mohit Rawat as CEO, who has led the company through to a groundbreaking acquisition by Novartis.\u00a0\u00a0<\/p>\n<p>Dr.\u00a0Roberto Solari, Venture Partner at Brandon Capital and Myricx Bio founding CEOsaid, &#8220;Myricx Bio\u00a0demonstrates the power of Brandon Capital\u2019s model: combining deep scientific conviction, hands-on company building, and disciplined early-stage investment.<\/p>\n<p>&#8220;When Brandon Capital first backed the\u00a0potential for\u00a0NMT\u00a0inhibition\u00a0based\u00a0on a new understanding of its\u00a0biology, there was no precedent for this approach. It was early, highly innovative, and\u00a0high risk. But we believed the science had the potential to create an entirely new class of cancer therapeutics. Today\u2019s acquisition by Novartis shows that judgment was right.\u201d\u00a0<\/p>\n<p>Dr.\u00a0Jonathan Tobin, Partner at Brandon Capital and Myricx Bio Director said, &#8220;We recognised that\u00a0NMTi-ADCs\u00a0could become the next-generation class of ADC payloads, and that with a growing pipeline of cytotoxic payloads there would become a need for a completely orthogonal mechanism.\u201d<\/p>\n<p>Dr.\u00a0Stephen\u00a0Thompson,\u00a0former\u00a0Myricx Bio\u00a0Director and Managing Partner at\u00a0Brandon Capitalsaid, &#8220;The success of Myricx Bio highlights Brandon Capital\u2019s ability to connect scientific, clinical, and commercial\u00a0expertise\u00a0across regions. We provide Australian portfolio companies with access to UK, European, and US capital, talent, and pharmaceutical networks, while enabling international companies to\u00a0benefit\u00a0from Australia\u2019s world-class translational research and clinical trial infrastructure.\u201d<\/p>\n<p>Mohit Rawat, CEO of Myricx Biosaid, &#8220;There is a widely recognised and critical unmet need for new ADC payloads that can improve the standard of care over current payloads, overcome payload resistance, improve tolerability and offer a wider therapeutic index. We are delighted that Novartis recognises the transformative promise of our NMTi-ADC platform to deliver this next-generation of potential first-in-class, highly differentiated ADC therapeutics.<\/p>\n<p>&#8220;This acquisition is a tremendous endorsement of the leadership of our NMTi-ADC platform, and the insights, innovation and achievements of our founders and team towards our mission of providing more effective and better tolerated therapeutic options for cancer patients. Together with Novartis, we look forward to building upon our work to transform the landscape of cancer treatment.\u201d<\/p>\n<p>About Brandon Capital &#8211; www.brandoncapital.vc <\/p>\n<p>Brandon Capital is headquartered in Melbourne with offices in Australia, New Zealand, the US and the UK. Australasia&#8217;s leading life sciences venture capital firm and is ranked in the top 50 biotech venture firms in Europe.<\/p>\n<p>To date, Brandon Capital has raised more than A$1.4 billion across six funds with investors including Hostplus, HESTA,\u00a0CSL, Aware Super, QIC, the Australian National Reconstruction Fund Corporation,\u00a0and the Government of Western Australia.<\/p>\n<p>The firm invests in high-potential medical science companies in Australia, New Zealand, the UK, Europe, and the US. Its unique model includes proprietary deal flow through Brandon BioCatalyst, a collaboration of over 50 of ANZ\u2019s leading medical research institutions, and its immersive corporate services structure enables portfolio companies to focus on research commercialisation.<\/p>\n<p>With more than 30 active companies in its portfolio, Brandon Capital has been sourcing and supporting the transition of world-leading science into world-leading businesses for nearly two decades. Its portfolio includes companies developing breakthrough therapies and technologies across oncology, neuroscience, ophthalmology, immunology, and other areas of high unmet medical need.\u00a0<\/p>\n<p>Notable Brandon Capital investments include: Aravax, developing therapies to address food allergy including peanut allergy based in Melbourne and Oxford; AstronautX, a neuroscience company with a focus on sleep based in London; AdvanCell,\u00a0a radioligand therapy company in Phase 2 trials\u00a0based in Brisbane\u00a0and\u00a0Boston;\u00a0CatalYm, developing an anti-GDF15 antibody in late-stage trials for cancer and cachexia based in Munich; and PolyActiva, developer of a sustained-release implant for glaucoma\u00a0based in Melbourne.<\/p>\n<p>For further information please contact<\/p>\n<p>Media &#8211; Australia<\/p>\n<p>Ruth Heenan, E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0or_5UQTCbdeGVVxK918Rp8x5p0sZEfIb5eX4PQUzWVQ_FUbcxW-Xr1DiPZCpDC4e0OWO98e00jKTjaDpQfX5SiKSEL6Bl8GjpLot2pDhxM=\" rel=\"nofollow noopener\" target=\"_blank\">[email\u00a0protected]<\/a> M: +61 (0)416 565332<\/p>\n<p>Andrew Geddes, E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TFQVhp4jLZ4a34dr2jo7OnkbcJCda8wyZnVMeRpTxu2Q4pYupqv2Bwah6yM0-H_QLPI26I2hx5LlkxAKHWKEnNBzO3EhL6d3ERUP3DA4yGRNsEosliyLMhzayRnXUzdd\" rel=\"nofollow noopener\" target=\"_blank\">[email\u00a0protected]<\/a> M: +61 (0)408 677 734<\/p>\n<p>Media &#8211; International<\/p>\n<p>Sue Charles, Charles Consultants E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kpsrhiyB1YBdFxtJRPhvYtDhj_6ZsueNO8b0ytzsbVgP58MsgLXVxnh6Q73rRrFPPIWx50l1rY7bHy1K6BjqN52GC0k_A9xw1X8-9-o6f7wA0mNOBKarEgZxgBcK4vB2l1xSq3y9No3wJz3r1KCciQ==\" rel=\"nofollow noopener\" target=\"_blank\">[email\u00a0protected]<\/a> M: +44 (0)7968 726585<\/p>\n<p>Chris Gardner, E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iGaByoooGewoTMVv9Srh88zwftzzkNRmHTh5Q0sQx8OwlgRNVwRFOf50VR9rH1NguUAc4x5dTHBZoWEbByRe8yH7tpjJcwoJJUdQpurKAYW52JuJfP2ygJ3F4boAUdor\" rel=\"nofollow noopener\" target=\"_blank\">[email\u00a0protected]<\/a> M: +44 (0)7956 031077<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7eOGYkiAv2k371kE9I2m3r0GoanDfwiIh9bOv_Hr2qq37JOqOaE93PtMI_8Tqrux9mRiB9hqP70X_RkYTJ4OKWv6A--cc7mpl63vPLIXBTuNL2uIvwjyykQISmGEDGqwGcGyC85fRixrffE-QBlhCqXa3XWr8G7tESbdNJycBR5eBOon0DTruPsbR1XqNqK6Xgd-r5__mRQqBTFGvIaVXIS4Xw-Q9u7Ijm2PFPHQLd6K5SyIlmWUz5vbAM-HsWgzj-4Hh42b2G3ikCTNDocMGA==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/8c5cc48f-24ff-46fb-bf7d-6339bdf3f4ef<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/07\/1783318995_229_Brandon-Capital.png\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) &#8212; Brandon Capital, Australasia\u2019s leading life sciences venture capital firm, today&hellip;\n","protected":false},"author":2,"featured_media":97944,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[21025,23166,12132,16576,48612,48610,2112,15755,48229,1124,4511,48611,967,206,4004,8396,7094,1408],"class_list":["post-97943","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-acquire","tag-advance","tag-agreement","tag-announces","tag-bio","tag-brandon","tag-cancer","tag-capital","tag-class","tag-company","tag-for","tag-myricx","tag-new","tag-novartis","tag-of","tag-portfolio","tag-therapeutics","tag-to"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116871600844843755","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/97943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=97943"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/97943\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/97944"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=97943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=97943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=97943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}